Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the HERG Screening Market Through 2034?
The market size of HERG screening has experienced significant expansion in recent years. The market forecast suggests an increase from $1.62 billion in 2024 to $1.84 billion in 2025, at a compound annual growth rate (CAGR) of 13.7%. The substantial growth during the historic period can be credited to the escalation in drug development processes, adherence to regulatory norms, enhanced awareness concerning cardiac safety, and the increasing frequency of cardiac disorders.
In the coming years, the HERG screening market is projected to experience swift expansion. It’s anticipated to surge to $2.88 billion by 2029, with a compound annual growth rate (CAGR) of 11.9%. The expected growth during the forecast period is linked to the rise of personalized medicine, the escalation of outsourced drug development operations, the emergence of new markets and research, and an emphasis on non-cardiac safety evaluations. The forecasted period will also witness significant trends such as the evolution of in vitro models, the unification of genomic and proteomic data, advancements in computational methods, a focus on the safety of pediatric drugs, and partnerships for data sharing and standardization.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp
What Are the Core Market Drivers Propelling Growth in the HERG Screening Industry?
The increase in heart disease patients is anticipated to boost the expansion of the HERG screening market. Heart diseases, also recognized as cardiovascular disorders, encompass a myriad of conditions that impact the heart and blood vessels, potentially leading to severe health issues. Factors such as unhealthy lifestyles, aging, genetic predispositions, diabetes, and metabolic syndrome contribute to these disorders. HERG screening is a critical tool for recognizing possible drug candidates, preventing harmful cardiac incidents which could trigger fatal cardiac arrhythmias, particularly torsade de pointes (TdP), and bettering patient outcomes. For example, a Centers for Disease Control and Prevention report from May 2023 showed that 1 in 20 U.S. adults over the age of 20 had cardiovascular diseases, with 695,000 suffering and 375,476 people dying from these conditions. Moreover, a March 2022 Office for National Statistics report stated that the death toll from heart attacks in the UK increased from the previous year to 20,061. Consequently, the escalating number of heart disease patients is fueling the HERG screening market’s growth.
How Is the HERG Screening Market Segmented?
The herg screening market covered in this report is segmented –
1) By Type: Gene KCNH2, Mutant KCNH2
2) By Ion Channel: Voltage-Gated, Ligand Gated
3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications
Subsegments:
1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2
2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=14392&type=smp
Which Regions Are Driving the Next Phase of the HERG Screening Market Growth?
North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Market Trends and Innovations Are Shaping the Future of the HERG Screening Industry?
Leading firms involved in the HERG screening market are shifting their focus towards new cutting-edge advanced solutions such as GLP-certified HERG screening services to improve cardiac safety evaluations during drug development procedures. This service pertains to good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) using the traditional whole-cell patch-clamp method. It guarantees that the screening adheres to regulatory guidelines like ICH S7A and ICH S7B, which are crucial for safety pharmacology studies in drug development. For example, in August 2023, Metrion Biosciences Ltd., a pharmaceutical firm based in the UK, introduced the good laboratory practice (GLP) certified hERG screening service. This service’s main intent is to expand Metrion’s assistance for small-molecule therapeutic development and to supplement the company’s existing cardiac safety service range. Furthermore, this service employs the traditional whole-cell patch-clamp technique to evaluate potential cardiac liabilities prior to initiating Phase 1 clinical trials in humans. It also provides regulatory guidance for safety pharmacology studies in drug development and provides clients with top-notch biology services for ion channel targets.
View the full report here:
https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report
How Is the HERG Screening Market Defined and What Are Its Core Parameters?
Human Ether-à-go-go-related gene (HERG) screening refers to the process of assessing the potential cardiotoxicity of a drug or compound. HERG screening is an important component of preclinical safety assessment in drug discovery and development, ensuring the safety and efficacy of novel therapeutic agents.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14392
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model